Incidence, outcomes, and risk factors of antituberculosis drugs induced liver injury in Thailand: A retrospective cohort study

被引:0
|
作者
Akkahadsee, Pattaraporn [1 ]
Jantharaksa, Sirot [1 ]
Sawangjit, Ratree [2 ]
Phumart, Panumart [3 ]
机构
[1] Mahasarakham Hosp, Maha Sarakham, Thailand
[2] Mahasarakham Univ, Fac Pharm, Dept Clin Pharm, Clin Trials & Evidence Based Synth Res Unit CTEBs, Maha Sarakham, Thailand
[3] Khon Kaen Univ, Dept Social & Adm Pharm, Khon Kaen, Thailand
来源
PHARMACY PRACTICE-GRANADA | 2024年 / 22卷 / 02期
关键词
tuberculosis; drug-induced liver injury; hepatotoxicity; risk factors; INDUCED HEPATOTOXICITY; TUBERCULOSIS PATIENTS; POLYMORPHISMS; PREVALENCE; MANAGEMENT; REGIMENS; HIV;
D O I
10.18549/PharmPract.2024.2.2965
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Tuberculosis (TB) is a persistent health concern in numerous regions, including Thailand. The adverse effects of tuberculosis (TB) treatments, particularly liver injuries, can complicate treatment protocols, thereby increasing the likelihood of treatment discontinuation and the risk of subsequent drug resistance. Objective: This study was conducted to investigate the incidence, predisposing factors, and treatment outcomes associated with antituberculosis drugs induced liver injury (ATDILI) in Northeastern Thailand. Methods: A retrospective analysis was conducted at Mahasarakham Hospital in 2019. Patient data were retrieved from hospital records and databases. Inclusion criteria included receiving a first-time TB diagnosis, starting a standard TB regimen, and having normal liver function. To compare baseline characteristics between ATDILI patients and controls, Chi-square tests and T -tests were used. Bivariate and multivariable regression analyses were conducted to identify factors associated with drug -induced hepatitis. Results: 346 of 602 TB patients (57.5%) were enrolled. The study found an incidence of ATDILI at 14.45% (50 cases), which is notably higher than the Thai average of 4.8%. Risk factors were identified as malnutrition (adjusted OR=6.71, 95%CI 3.11:14.45), concurrent diseases (adjusted OR=2.42, 95%CI 1.20:4.89), and alcohol consumption (adjusted OR=4.24, 95%CI 1.45:12.38). In terms of therapeutic outcomes, only 18 patients were cured (36.0%). The probability of hepatotoxic events was addressed during the initial treatment phase, emphasizing the critical need for rigorous liver function monitoring during the first month of TB therapy. The ATDILI group had a mortality rate of 16%, which was higher than the national TB -related average of 8.2%. Conclusion: The marked presence of ATDILI in the cohort under study accentuates the immediate need for enhanced clinical monitoring, especially among susceptible groups. It is imperative to implement strategies aimed at early detection, prompt intervention, and holistic management of ATDILI, complemented by endeavors to boost cure rates for the affected population.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Incidence of side effects of antituberculosis drugs and their related factors in northern Iran: a retrospective cohort study
    Kheradmand, Motahareh
    Afshari, Mahdi
    Aarabi, Mohsen
    Abedi, Siavosh
    Parsaee, Mohammadreza
    Nezammahalleh, Asghar
    Moosazadeh, Mahmood
    GMS HYGIENE AND INFECTION CONTROL, 2024, 19
  • [2] Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis
    Kumar, Ramesh
    Kumar, Abhishek
    Patel, Rishabh
    Prakash, Sabbu Surya
    Kumar, Sudhir
    Surya, Himanshu
    Marrapu, Sudheer
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2025, 44 (01) : 35 - 46
  • [3] Characteristics and risk factors for antituberculosis drug-induced liver injury in a cohort of patients with cirrhosis in a tertiary referral university teaching hospital in Thailand
    Laoveeravat, Passisd
    Wongjarupong, Nicha
    Phathong, Chonlada
    Hurst, Cameron
    Treeprasertsuk, Sombat
    Rerknimitr, Rungsun
    Chaiteerakij, Roongruedee
    ASIAN BIOMEDICINE, 2018, 12 (02) : 65 - 74
  • [4] Incidence, risk factors and outcomes of checkpoint inhibitor- induced liver injury: A 10-year real-world retrospective cohort study
    Atallah, Edmond
    Welsh, Sarah J.
    O'Carrigan, Brent
    Oshaughnessy, Ana
    Dolapo, Igboin
    Kerr, Andrew S.
    Kucharczak, Joanna
    Lee, Colin Y. C.
    Crooks, Colin
    Hicks, Amy
    Chimakurthi, Chenchu Ramu
    Rao, Ankit
    Franks, Hester
    Patel, Poulam M.
    Aithal, Guruprasad P.
    JHEP REPORTS, 2023, 5 (10)
  • [5] Antituberculosis Drug-induced Liver Injury in Children Incidence and Risk Factors During the Two-month Intensive Phase of Therapy
    Gafar, Fajri
    Arifin, Helmi
    Jurnalis, Yusri D.
    Yani, Finny F.
    Fitria, Najmiatul
    Alffenaar, Jan-Willem C.
    Wilffert, Bob
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (01) : 50 - 53
  • [6] Incidence and risk factors of drug-induced liver injury
    Li, Xiaoyun
    Tang, Jieting
    Mao, Yimin
    LIVER INTERNATIONAL, 2022, 42 (09) : 1999 - 2014
  • [7] The effect of statins on the risk of antituberculosis drug-induced liver injury among patients with active tuberculosis: A cohort study
    Huang, Chun-Kai
    Huang, Jei-Yie
    Chang, Chin-Hao
    Tsai, Shang-Jie
    Shu, Chin-Chung
    Wang, Hao-Chien
    Chien, Kuo-Liong
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2024, 57 (03) : 498 - 508
  • [8] Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury
    Huang, Yi-Shin
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (04) : 169 - 173
  • [9] Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study
    Yang, Hong-Yi
    Guo, Dai-Hong
    Jia, Wang-Ping
    Zhu, Man
    Xu, Yuan-Jie
    Wang, Xiao-Yu
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 389 - 395
  • [10] Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury
    Liu, Quanxian
    Huang, Lu
    Yan, Hong
    Zong, Zhaojing
    Chen, Zhenyong
    Wu, Xiaoyan
    Chen, Ling
    Lan, Yuanbo
    FRONTIERS IN PHARMACOLOGY, 2024, 15